NCT04089865View on ClinicalTrials.gov

Oral Versus Intravenous Tranexamic Acid

PHASE4CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

November 10, 2021

Study Completion Date

November 10, 2021

Conditions

Blood LossBlood Transfusion

Interventions

DRUG

Tranexamic Acid

Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.

Trial Locations (1)

10021

Hospital for Special Surgery, New York

All Listed Sponsors

lead

Hospital for Special Surgery, New York

OTHER

NCT04089865 - Oral Versus Intravenous Tranexamic Acid | Biotech Hunter | Biotech Hunter